Q3 FY2026 · ended Sep 30, 2026 · Revenue $1.72B, +10.5% YoY · Filed Nov 4, 2026
Edwards Lifesciences Corporation (EW) files with the SEC under industry code 3842, Orthopedic, Prosthetic & Surgical Appliances & Supplies. In Q3 of fiscal 2026, the quarter ended Sep 30, 2026, it reported revenue of $1.7 billion and net income of $307.5 million. Free cash flow was $506.7 million. As of Sep 30, 2026 it held $4.9 billion in cash and investments and $704.5 million in total debt.
Company profile
- Industry
- Orthopedic, Prosthetic & Surgical Appliances & Supplies (SIC 3842)
- Listed as
- EW (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Irvine, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1099800
- Former names
- CVG CONTROLLED INC (until Jan 21, 2000)
Other Orthopedic, Prosthetic & Surgical Appliances & Supplies companies
- Intuitive Surgical Inc ISRG
- STERIS plc STE
- Zimmer Biomet Holdings, Inc. ZBH
- Smith & Nephew PLC SNN
- Align Technology Inc ALGN
- MSA Safety Inc MSA
- Establishment Labs Holdings Inc. ESTA
- Cadre Holdings, Inc. CDRE
All 29 Orthopedic, Prosthetic & Surgical Appliances & Supplies companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $1.7B | $1.7B | $1.6B | $1.6B | $1.6B |
| Operating income | $299.1M | $513.2M | $477.6M | $151.1M | $307.1M |
| Net income | $307.5M | $241.9M | $380.7M | $91.2M | $291.1M |
| Diluted EPS | $0.53 | $0.42 | $0.66 | $0.16 | $0.50 |
| Operating cash flow | $570.3M | $651.9M | $43.8M | $450.9M | $573.7M |
| Free cash flow | $506.7M | $585.0M | -$21.1M | $353.5M | $516.2M |
| Total assets | $14.1B | $13.9B | $13.3B | $13.7B | $13.3B |
| Total liabilities | $3.2B | $3.1B | $3.0B | $3.4B | $3.1B |
| Stockholders' equity | $10.9B | $10.6B | $10.3B | $10.3B | $10.2B |
| Cash and investments | $4.9B | $4.5B | $4.0B | $4.5B | $4.1B |
| Total debt | $704.5M | $704.4M | $702.9M | $705.4M | $700.3M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 4, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 4, 2026 | Nov 4, 2026 |
| 8-K |
Current report
Officer or director change
|
Aug 28, 2026 | Aug 25, 2026 |
| 10-Q | Quarterly report | Aug 4, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Jul 23, 2026 | Jul 23, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
May 8, 2026 | May 7, 2026 |
All 1000 Edwards Lifesciences Corporation SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.